Drug intelligence / Profile preview

PH-804

Development stage: Preclinical
Lead developer: Phio Pharmaceuticals
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

PH-804 is an investigational immuno-oncology therapeutic developed by Phio Pharmaceuticals. It is based on the company's proprietary self-delivering RNAi (INTASYL) therapeutic platform, which utilizes RNA interference (RNAi) technology. The drug is part of Phio Pharmaceuticals' pipeline aimed at advancing immuno-oncology programs.

Other names: sd-rxRNA targeting TIGIT

Targets

TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on PH-804.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PH-804.

Explore the full profile